CO5130020A1 - Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide - Google Patents
Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroideInfo
- Publication number
- CO5130020A1 CO5130020A1 CO99052525A CO99052525A CO5130020A1 CO 5130020 A1 CO5130020 A1 CO 5130020A1 CO 99052525 A CO99052525 A CO 99052525A CO 99052525 A CO99052525 A CO 99052525A CO 5130020 A1 CO5130020 A1 CO 5130020A1
- Authority
- CO
- Colombia
- Prior art keywords
- hardness
- increasing
- tenacity
- manufacture
- product containing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 1
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- 229960001319 parathyroid hormone Drugs 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
Un método para incrementar la dureza y/o tenacidad del hueso en un sitio objeto de un trauma potencial ó real en un sujeto en necesidad de dicho tratamiento, método que comprende la administración al sujeto de una cantidadeficaz de una hormona paratiroides.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9715198P | 1998-08-19 | 1998-08-19 | |
| US9974698P | 1998-09-10 | 1998-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5130020A1 true CO5130020A1 (es) | 2002-02-27 |
Family
ID=26792729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99052525A CO5130020A1 (es) | 1998-08-19 | 1999-08-19 | Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6977077B1 (es) |
| EP (3) | EP1059933B1 (es) |
| JP (5) | JP2002523375A (es) |
| KR (1) | KR100454207B1 (es) |
| CN (1) | CN1205997C (es) |
| AR (1) | AR033639A1 (es) |
| AT (1) | ATE231000T1 (es) |
| AU (1) | AU746277B2 (es) |
| BR (1) | BR9909445A (es) |
| CA (1) | CA2325371C (es) |
| CO (1) | CO5130020A1 (es) |
| CY (2) | CY1113343T1 (es) |
| CZ (1) | CZ301017B6 (es) |
| DE (2) | DE69904918T2 (es) |
| DK (4) | DK1059933T3 (es) |
| DZ (1) | DZ2873A1 (es) |
| EA (1) | EA003362B1 (es) |
| ES (4) | ES2393200T3 (es) |
| HK (3) | HK1030545A1 (es) |
| HR (1) | HRP20000755A2 (es) |
| HU (2) | HU1200430D0 (es) |
| ID (1) | ID29039A (es) |
| IL (2) | IL138829A0 (es) |
| MY (1) | MY129227A (es) |
| NO (2) | NO323984B1 (es) |
| NZ (1) | NZ507056A (es) |
| PE (1) | PE20001089A1 (es) |
| PL (1) | PL201688B1 (es) |
| PT (4) | PT1059933E (es) |
| TR (1) | TR200003455T2 (es) |
| TW (1) | TW576747B (es) |
| UA (1) | UA72205C2 (es) |
| WO (1) | WO2000010596A1 (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| DZ2873A1 (fr) | 1998-08-19 | 2003-12-15 | Lilly Co Eli | Procédé pour augmenter la dureté et la rigidité osseuse. |
| US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| EP1222465A1 (en) * | 1999-09-20 | 2002-07-17 | Eli Lilly And Company | Method for monitoring treatment with a parathyroid hormone |
| US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
| CA2472472A1 (en) | 2002-01-10 | 2003-07-24 | Osteotrophin Llc | Treatment of bone disorders with skeletal anabolic drugs |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| JP2007505883A (ja) * | 2003-09-19 | 2007-03-15 | ファイザー・プロダクツ・インク | ２−アルキリデン−１９−ノル−ビタミンｄ誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法 |
| US20060189533A1 (en) * | 2004-05-10 | 2006-08-24 | Nastech Pharmaceutical Company Inc. | Stable pharmaceutical dosage forms of teriparatide |
| JP2007537274A (ja) * | 2004-05-10 | 2007-12-20 | ナステック ファーマスーティカル カンパニー インク． | 副甲状腺ホルモンの粘膜送達を増強するための組成物及び方法 |
| US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
| US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
| EP1744683B1 (en) | 2004-05-13 | 2016-03-16 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| US7648965B2 (en) | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| WO2006073711A2 (en) | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| CA2608016A1 (en) * | 2005-05-11 | 2006-11-23 | Unigene Laboratories, Inc. | Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp |
| US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
| EP1945245A2 (en) * | 2005-11-10 | 2008-07-23 | The Board of Control of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| US20080119408A1 (en) * | 2006-07-07 | 2008-05-22 | Nastech Pharmaceutical Company Inc. | Pth formulations for intranasal delivery |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| PT2136850E (pt) | 2007-04-13 | 2012-04-27 | Kuros Biosurgery Ag | Selante tecidual polimérico |
| US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
| EP2217260B1 (en) * | 2007-12-04 | 2016-11-09 | Ben-Gurion University Of The Negev Research And Development Authority | Amphiphilic peptide matrices for treatment of osteoporosis |
| CA2710798A1 (en) | 2007-12-28 | 2009-07-09 | Kuros Biosurgery Ag | Pdgf fusion proteins incorporated into fibrin foams |
| KR102335703B1 (ko) | 2009-09-09 | 2021-12-07 | 아사히 가세이 파마 가부시키가이샤 | 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제 |
| BR112012013725A2 (pt) | 2009-12-07 | 2017-01-10 | Univ Michigan Tech | paratormônio de urso preto e métodos de usar o paratormônio de uso preto. |
| US9295663B2 (en) | 2010-07-14 | 2016-03-29 | Abbott Cardiovascular Systems Inc. | Drug coated balloon with in-situ formed drug containing microspheres |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| ES2882852T3 (es) | 2011-03-16 | 2021-12-02 | Kuros Biosurgery Ag | Formulación farmacéutica para la utilización en la fusión espinal |
| ES2761635T3 (es) | 2011-06-07 | 2020-05-20 | Asahi Kasei Pharma Corp | Preparación liofilizada que contiene PTH de alta pureza y método para producirla |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| WO2017136195A1 (en) | 2016-02-01 | 2017-08-10 | Eli Lilly And Company | Parathyroid hormone – anti-rankl antibody fusion compounds |
| US20190381341A1 (en) * | 2017-02-01 | 2019-12-19 | The Johns Hopkins University | Parathyroid hormone and regeneration of degenerative discs disease |
| EP3685849A4 (en) * | 2017-09-22 | 2021-12-22 | Asahi Kasei Pharma Corporation | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY |
| WO2020090174A1 (ja) | 2018-10-29 | 2020-05-07 | 旭化成ファーマ株式会社 | 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法 |
| EP4010360A1 (en) | 2019-08-09 | 2022-06-15 | Flagship Pioneering Innovations VI, LLC | Modulators of parathyroid hormone receptor (pthr1) |
| GB2590692A (en) * | 2019-12-24 | 2021-07-07 | Corthotec Ltd | Composition for improved bone fracture healing |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| IL78342A (en) | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5208041A (en) | 1991-05-23 | 1993-05-04 | Allelix Biopharmaceuticals Inc. | Essentially pure human parathyroid hormone |
| US5556940A (en) | 1994-06-20 | 1996-09-17 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| JPH0873376A (ja) * | 1994-09-07 | 1996-03-19 | Asahi Chem Ind Co Ltd | 骨粗鬆症治療薬 |
| US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
| WO1996019246A1 (en) * | 1994-12-19 | 1996-06-27 | Beth Israel Hospital Association | Continuous low-dose administration of parathyroid hormone or its agonist |
| CA2206657C (en) * | 1994-12-22 | 2009-05-19 | Astra Aktiebolag | Therapeutic preparation for inhalation containing parathyroid hormone, pth |
| JPH08310965A (ja) * | 1995-05-16 | 1996-11-26 | Chugai Pharmaceut Co Ltd | 骨癒合促進剤 |
| RU2224539C2 (ru) * | 1997-09-09 | 2004-02-27 | Ф.Хоффманн-Ля Рош Аг | Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр) |
| MY120063A (en) | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
| US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| DZ2873A1 (fr) | 1998-08-19 | 2003-12-15 | Lilly Co Eli | Procédé pour augmenter la dureté et la rigidité osseuse. |
| US6907597B1 (en) | 2000-10-13 | 2005-06-14 | Ati International Srl | Method and apparatus for constructing an executable program in memory |
| US6967759B2 (en) | 2001-12-31 | 2005-11-22 | Texas Instruments Incorporated | Pulse width modulation sequence generation |
| JP5796714B2 (ja) | 2012-01-13 | 2015-10-21 | 株式会社リコー | 定着装置及び画像形成装置 |
| EP2949301B1 (en) | 2014-05-27 | 2018-04-18 | The Procter and Gamble Company | Absorbent core with curved and straight absorbent material areas |
-
1999
- 1999-08-18 DZ DZ990173A patent/DZ2873A1/xx active
- 1999-08-18 AR ARP990104133A patent/AR033639A1/es unknown
- 1999-08-19 DK DK99942350T patent/DK1059933T3/da active
- 1999-08-19 DK DK10180447.4T patent/DK2266598T3/en active
- 1999-08-19 AU AU55750/99A patent/AU746277B2/en not_active Expired
- 1999-08-19 ES ES06027055T patent/ES2393200T3/es not_active Expired - Lifetime
- 1999-08-19 EP EP99942350A patent/EP1059933B1/en not_active Revoked
- 1999-08-19 DK DK15152726.4T patent/DK2907522T3/en active
- 1999-08-19 PT PT99942350T patent/PT1059933E/pt unknown
- 1999-08-19 UA UA2000095457A patent/UA72205C2/uk unknown
- 1999-08-19 EP EP10180447.4A patent/EP2266598B1/en not_active Expired - Lifetime
- 1999-08-19 CO CO99052525A patent/CO5130020A1/es unknown
- 1999-08-19 DK DK06027055.0T patent/DK1769804T3/da active
- 1999-08-19 AT AT99942350T patent/ATE231000T1/de not_active IP Right Cessation
- 1999-08-19 KR KR10-2001-7002092A patent/KR100454207B1/ko not_active IP Right Cessation
- 1999-08-19 NZ NZ507056A patent/NZ507056A/en not_active IP Right Cessation
- 1999-08-19 PL PL343595A patent/PL201688B1/pl not_active IP Right Cessation
- 1999-08-19 WO PCT/US1999/018961 patent/WO2000010596A1/en active IP Right Grant
- 1999-08-19 PT PT06027055T patent/PT1769804E/pt unknown
- 1999-08-19 HU HUP1200430 patent/HU1200430D0/hu not_active Application Discontinuation
- 1999-08-19 US US09/647,278 patent/US6977077B1/en not_active Expired - Lifetime
- 1999-08-19 ES ES99942350T patent/ES2190244T3/es not_active Expired - Lifetime
- 1999-08-19 EP EP15152726.4A patent/EP2907522B1/en not_active Revoked
- 1999-08-19 BR BR9909445-2A patent/BR9909445A/pt not_active Application Discontinuation
- 1999-08-19 PT PT15152726T patent/PT2907522T/pt unknown
- 1999-08-19 CZ CZ20004134A patent/CZ301017B6/cs not_active IP Right Cessation
- 1999-08-19 CA CA002325371A patent/CA2325371C/en not_active Expired - Lifetime
- 1999-08-19 HU HU0101594A patent/HU230697B1/hu unknown
- 1999-08-19 DE DE69904918T patent/DE69904918T2/de not_active Expired - Lifetime
- 1999-08-19 TR TR2000/03455T patent/TR200003455T2/xx unknown
- 1999-08-19 PT PT101804474T patent/PT2266598T/pt unknown
- 1999-08-19 MY MYPI99003553A patent/MY129227A/en unknown
- 1999-08-19 ES ES10180447.4T patent/ES2621653T3/es not_active Expired - Lifetime
- 1999-08-19 ID IDW20010612A patent/ID29039A/id unknown
- 1999-08-19 IL IL13882999A patent/IL138829A0/xx unknown
- 1999-08-19 JP JP2000565916A patent/JP2002523375A/ja active Pending
- 1999-08-19 CN CNB998083534A patent/CN1205997C/zh not_active Expired - Lifetime
- 1999-08-19 ES ES15152726.4T patent/ES2549551T3/es not_active Expired - Lifetime
- 1999-08-19 EA EA200001015A patent/EA003362B1/ru not_active IP Right Cessation
- 1999-08-19 PE PE1999000839A patent/PE20001089A1/es not_active Application Discontinuation
- 1999-08-19 DE DE15152726.4T patent/DE15152726T1/de active Pending
- 1999-10-26 TW TW088114185A patent/TW576747B/zh not_active IP Right Cessation
-
2000
- 2000-10-03 IL IL138829A patent/IL138829A/en unknown
- 2000-11-06 HR HR20000755A patent/HRP20000755A2/hr not_active Application Discontinuation
- 2000-11-24 NO NO20005947A patent/NO323984B1/no not_active IP Right Cessation
-
2001
- 2001-02-14 HK HK01101056A patent/HK1030545A1/xx unknown
-
2005
- 2005-04-05 US US11/098,894 patent/US7163684B2/en not_active Expired - Lifetime
-
2007
- 2007-06-11 NO NO20072983A patent/NO20072983L/no not_active Application Discontinuation
- 2007-10-04 HK HK07110798.6A patent/HK1102496A1/xx unknown
-
2010
- 2010-10-29 JP JP2010244314A patent/JP2011021035A/ja not_active Withdrawn
-
2012
- 2012-11-14 CY CY20121101096T patent/CY1113343T1/el unknown
-
2014
- 2014-03-25 JP JP2014061763A patent/JP6177718B2/ja not_active Expired - Lifetime
- 2014-10-03 JP JP2014204577A patent/JP2015028065A/ja not_active Withdrawn
-
2016
- 2016-01-18 HK HK16100519.4A patent/HK1212602A1/zh not_active IP Right Cessation
-
2017
- 2017-06-26 JP JP2017124301A patent/JP2017190332A/ja not_active Withdrawn
- 2017-10-13 CY CY20171101077T patent/CY1119552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5130020A1 (es) | Metodo para incrementar la dureza y tenacidad del hueso proceso para la manufactura de un medicamento que contiene una hormona paratiroide | |
| MXPA03003960A (es) | Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos. | |
| EP0830138A4 (en) | USE OF FIBROBLAST GROWTH FACTORS TO STIMULATE BONE GROWTH | |
| ECSP055739A (es) | Anticuerpos de neutralización contra gdf-8, y sus usos | |
| ATE319812T1 (de) | Knochen-vorläufer-zellen: zusammensetzungen und methoden | |
| DK0881908T3 (da) | Anvendelse af fiberblastvækstfaktorer til stimulering af knoglevækst | |
| GB0001309D0 (en) | Valve arrangement | |
| MXPA04005583A (es) | Composicion para la promocion del crecimiento oseo y mantenimiento de la salud osea. | |
| IL154888A (en) | Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid | |
| GB0109146D0 (en) | Treatment of type 2 diabetes | |
| HK1001973A1 (en) | Sulfonamides | |
| BR9916879A (pt) | Composição e método para tratamento do câncer utilizando óleos essenciais vegetais naturais | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| SE9404196D0 (sv) | New antithrombotic formulation | |
| IL113941A (en) | Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them | |
| FI964332A (fi) | Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen | |
| EP1072273A4 (en) | VASKULARISIERUNGSINHIBITOREN | |
| ITMI931649A1 (it) | Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico | |
| SE9603725D0 (sv) | New teatment | |
| BG105275A (en) | Tan-1057 derivatives | |
| NZ326345A (en) | Composition containing diosgenin | |
| MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
| ATE157255T1 (de) | Zusammensetzung zur bekämpfung von dermatomykosen und deren erregern sowie von schweissbildung und körpergeruch | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| PL375354A1 (en) | Use of treosulfan and derivatives thereof for treating multiple sclerosis |